An interventional study of Red Propolis and Placebo Control in Kidney Disease, Oxidative Stress and Chronic Kidney Disease, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Kidney Diseases with a site in Brazil — 5 open to participants now, 11 under way, 8 of them phase 3. Kidney Diseases · Brazil.
Among the 30 studies in Kidney Diseases with a site in Brazil, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 30th registered.
970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.
Browse Kidney Diseases studies →5 of the 30 studies in Kidney Diseases with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 35 more countries
Ages 50+
Hospital do Rim e Hipertensão · Sites in Brazil
Dimerix Bioscience Pty Ltd · Sites in Brazil, United States, Argentina and 18 more countries
Ages 12–80
Population Health Research Institute · Sites in Brazil, Argentina, Bangladesh and 22 more countries
Ages 35–70
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 14 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 647 interventional studies indexed under Kidney Diseases.
Median enrollment 394 across the 24 interventional studies, 1,879 across the 6 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
Universidade Federal Fluminense is the lead sponsor of 72 studies on the registry; 13 are open to participants now.
Universidade Federal Fluminense has 2 studies filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Kidney Diseases with a site in Brazil that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Kidney Diseases with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months.
Dietary Supplement: Red Propolis
Patients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months.
Other: Placebo Control
Participants will receive 200mg of red propolis capsules per day for two months.
Participants will receive 200mg of placebo capsules per day for two months.
Change in inflammatory biomarkers
Changes in the IL-6 and TNF-α
Time frame: 8 weeks
Ran from Sep 2025 to primary completion in Nov 2025, 2 months.
Of 127 non-industry interventional studies with no phase under Kidney Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's 2 months is below that.
Counting every sponsor, half of 147 studies reached it within 34 months; a quarter within 13 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade Federal Fluminense